JP5209463B2 - アシル化ｇｌｐ−１化合物 - Google Patents

アシル化ｇｌｐ−１化合物 Download PDF

Info

Publication number
JP5209463B2
JP5209463B2 JP2008501334A JP2008501334A JP5209463B2 JP 5209463 B2 JP5209463 B2 JP 5209463B2 JP 2008501334 A JP2008501334 A JP 2008501334A JP 2008501334 A JP2008501334 A JP 2008501334A JP 5209463 B2 JP5209463 B2 JP 5209463B2
Authority
JP
Japan
Prior art keywords
ethoxy
glp
peptide
acetyl
arg34
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008501334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008533105A (ja
JP2008533105A5 (index.php
Inventor
ラウ、イェスパー
デールワルド、フロレンシオ・ザラゴザ
ステッペンセン、ヘンリク
ブロホ、パウ
ハンセン、トマス・クルーセ
マドセン、キエルド
Original Assignee
ノヴォ ノルディスク アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36821525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5209463(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノヴォ ノルディスク アー／エス filed Critical ノヴォ ノルディスク アー／エス
Publication of JP2008533105A publication Critical patent/JP2008533105A/ja
Publication of JP2008533105A5 publication Critical patent/JP2008533105A5/ja
Application granted granted Critical
Publication of JP5209463B2 publication Critical patent/JP5209463B2/ja
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
JP2008501334A 2005-03-18 2006-03-20 アシル化ｇｌｐ−１化合物 Active JP5209463B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102171.5 2005-03-18
EP05102171 2005-03-18
PCT/EP2006/060855 WO2006097537A2 (en) 2005-03-18 2006-03-20 Acylated glp-1 compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010009025A Division JP4585037B2 (ja) 2005-03-18 2010-01-19 アシル化ｇｌｐ−１化合物
JP2012242654A Division JP2013063984A (ja) 2005-03-18 2012-11-02 アシル化ｇｌｐ−１化合物

Publications (3)

Publication Number Publication Date
JP2008533105A JP2008533105A (ja) 2008-08-21
JP2008533105A5 JP2008533105A5 (index.php) 2008-11-06
JP5209463B2 true JP5209463B2 (ja) 2013-06-12

Family

ID=36821525

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008501334A Active JP5209463B2 (ja) 2005-03-18 2006-03-20 アシル化ｇｌｐ−１化合物
JP2010009025A Active JP4585037B2 (ja) 2005-03-18 2010-01-19 アシル化ｇｌｐ−１化合物
JP2012242654A Withdrawn JP2013063984A (ja) 2005-03-18 2012-11-02 アシル化ｇｌｐ−１化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010009025A Active JP4585037B2 (ja) 2005-03-18 2010-01-19 アシル化ｇｌｐ−１化合物
JP2012242654A Withdrawn JP2013063984A (ja) 2005-03-18 2012-11-02 アシル化ｇｌｐ−１化合物

Country Status (24)

Country Link
US (2) US8129343B2 (index.php)
EP (2) EP1863839B1 (index.php)
JP (3) JP5209463B2 (index.php)
KR (1) KR101205272B1 (index.php)
CN (3) CN104402989A (index.php)
AT (1) ATE476446T1 (index.php)
AU (1) AU2006224536B9 (index.php)
BE (1) BE2018C016I2 (index.php)
BR (2) BRPI0607762B8 (index.php)
CA (1) CA2601784C (index.php)
DE (1) DE602006015928D1 (index.php)
DK (2) DK1863839T3 (index.php)
ES (2) ES2557313T3 (index.php)
HU (2) HUE028194T2 (index.php)
IL (1) IL184051A (index.php)
MX (1) MX2007011220A (index.php)
NL (1) NL300936I2 (index.php)
NO (2) NO337946B1 (index.php)
PL (2) PL2322546T3 (index.php)
PT (2) PT2322546E (index.php)
RU (1) RU2434019C3 (index.php)
TW (2) TWI362392B (index.php)
WO (1) WO2006097537A2 (index.php)
ZA (1) ZA200707261B (index.php)

Families Citing this family (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
MXPA06002941A (es) * 2003-09-19 2006-05-31 Novo Nordisk As Derivados de enlace a albumina de peptidos terapeuticos.
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
EP1799711B1 (en) 2004-10-07 2012-06-20 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CA2596926A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
ES2426445T3 (es) 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) * 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
CN101842109B (zh) * 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
EP2190873B1 (en) * 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
HUE030383T2 (en) 2007-11-16 2017-05-29 Novo Nordisk As Stable pharmaceutical formulations containing liraglutide and deglates
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
KR101755434B1 (ko) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
AU2009228093B2 (en) 2008-03-28 2014-08-07 Neurelis, Inc. Administration of benzodiazepine compositions
AU2009244797B2 (en) 2008-05-07 2015-01-22 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
WO2010015668A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CA2747825A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
AU2010207721B2 (en) 2009-01-23 2015-03-26 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
WO2010142665A1 (en) * 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
WO2011006497A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
JP5411366B2 (ja) 2009-12-16 2014-02-12 ノヴォ ノルディスク アー／エス 二重アシル化ｇｌｐ−１誘導体
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
US20130035285A1 (en) 2010-03-26 2013-02-07 Novo Nordisk A/S Novel glucagon analogues
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CA2797431C (en) * 2010-04-27 2016-06-21 Zhejiang Beta Pharma Inc. Glucagon-like peptide-1 analogue and use thereof
CN102186881B (zh) * 2010-04-27 2015-04-08 贝达药业股份有限公司 胰高血糖素样肽-1衍生物及其应用
SG185604A1 (en) * 2010-05-17 2012-12-28 Zhejiang Beta Pharma Inc Novel glucagon like peptide analogs, composition, and method of use
WO2012016419A1 (zh) * 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US20140004198A1 (en) 2011-01-19 2014-01-02 Novo Nordisk A/S Glp-1 particles and compositions
JP2014502984A (ja) 2011-01-19 2014-02-06 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物
JP2014510739A (ja) * 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
JP5871905B2 (ja) * 2011-03-30 2016-03-01 ベータ ファーマシューティカルズ カンパニー リミテッド グルカゴン様ペプチド−１類似体およびその使用
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives
KR102093463B1 (ko) * 2011-04-12 2020-03-26 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
WO2012174158A2 (en) 2011-06-14 2012-12-20 Hale Biopharma Ventures, Llc Administration of benzodiazepine
US9353172B2 (en) 2011-07-18 2016-05-31 Arts Biologics A/S Long acting biologically active luteinizing hormone (LH) compound
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
JP6046161B2 (ja) 2011-12-29 2016-12-14 ノヴォ ノルディスク アー／エス 非タンパク質新生アミノ酸を含むジペプチド
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
HRP20181817T1 (hr) 2012-02-15 2018-12-28 Novo Nordisk A/S Anitijela koja vezuju protein 1 prepoznavanja peptidoglikana
TWI605061B (zh) 2012-02-15 2017-11-11 諾佛 儂迪克股份有限公司 會結合及阻斷表現在骨髓細胞上觸發受體－１（ｔｒｅｍ－１）之抗體
HRP20190489T1 (hr) 2012-03-22 2019-05-03 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
PL3542790T3 (pl) 2012-03-22 2024-02-26 Novo Nordisk A/S Kompozycje zawierające substancję dostarczającą i ich przygotowanie
SMT201800491T1 (it) 2012-03-22 2018-11-09 Novo Nordisk As Composizioni di peptidi glp-1 e relativa preparazione
KR102266299B1 (ko) * 2012-03-22 2021-06-18 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
WO2013167455A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
HRP20200889T1 (hr) 2012-07-01 2020-09-04 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp-1
SG11201500375PA (en) 2012-07-23 2015-02-27 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
CN104717972A (zh) * 2012-10-17 2015-06-17 诺和诺德A/S（股份有限公司） 用于口服肽递送的脂肪酸酰化氨基酸
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX369259B (es) 2013-05-02 2019-11-04 Novo Nordisk As Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
ES2646538T3 (es) 2013-06-20 2017-12-14 Novo Nordisk A/S Derivados de GLP-1 y sus usos
BR112015032875A2 (pt) 2013-07-04 2017-11-07 Novo Nordisk As derivados de peptídeos do tipo glp-1, e usos dos mesmos
WO2015022400A1 (en) 2013-08-15 2015-02-19 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN105792851B (zh) 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
MX2016010599A (es) 2014-02-18 2016-11-18 Novo Nordisk As Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
CN106132985B (zh) 2014-04-07 2020-10-13 诺和诺德股份有限公司 双酰化glp-1化合物
WO2015169789A1 (en) 2014-05-07 2015-11-12 Novo Nordisk A/S Treatment of diabetes type 1 using glp-1 and anti-il-21
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
TN2017000008A1 (en) 2014-07-17 2018-07-04 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
EP3530671A3 (en) 2014-09-05 2019-11-13 University of Copenhagen Gip peptide analogues
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
MX381640B (es) 2014-10-29 2025-03-04 Zealand Pharma As Metodos y compuestos agonistas de gip.
ES2739289T3 (es) 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
HK1246156B (en) 2014-12-23 2020-03-27 Novo Nordisk A/S FGF21 derivatives and their uses
WO2016120380A1 (en) * 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating
ES2975708T3 (es) 2015-01-29 2024-07-12 Novo Nordisk As Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
EP3283507B8 (en) 2015-04-16 2019-11-13 Zealand Pharma A/S Acylated glucagon analogue
BR112017026853A2 (pt) * 2015-06-16 2018-08-14 Sun Pharma Advanced Research Company Limited composição de ação prolongada
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN106554403B (zh) * 2015-09-25 2021-08-31 博瑞生物医药（苏州）股份有限公司 艾塞那肽修饰物及其用途
CN106554408A (zh) * 2015-09-30 2017-04-05 天津药物研究院有限公司 长效胰高血糖素样肽-1类似物二聚体及其应用
CN106554409B (zh) * 2015-09-30 2020-04-07 天津药物研究院有限公司 一种长效胰高血糖素样肽-1类似物及其应用
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
CN106928343A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 索玛鲁肽的制备方法
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CN107266557B (zh) * 2016-04-06 2020-04-07 天津药物研究院有限公司 一种聚乙二醇修饰的胰高血糖素样肽-1类似物
ES2928007T3 (es) * 2016-04-28 2022-11-14 Novo Nordisk As Semaglutida en afecciones cardiovasculares
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
WO2018078112A1 (en) 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
MY194504A (en) 2016-12-16 2022-11-30 Novo Nordisk As Insulin containing pharmaceutical compositions
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
EP3592376A1 (en) * 2017-03-08 2020-01-15 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
JP2020521784A (ja) 2017-05-31 2020-07-27 ユニバーシティ オブ コペンハーゲン 長時間作用性ｇｉｐペプチド類似体
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
PE20200720A1 (es) * 2017-07-19 2020-07-21 Novo Nordisk As Compuestos bifuncionales
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
MA50233A (fr) 2017-09-10 2020-07-22 Novo Nordisk As Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
EP3689942B1 (en) 2017-09-29 2024-06-19 Hanmi Pharm. Co., Ltd. Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
MA50358A (fr) 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
EP3728304B1 (en) * 2017-12-21 2025-02-12 Bachem Holding AG Solid phase synthesis of acylated peptides
TWI804571B (zh) 2018-02-02 2023-06-11 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑及n-(8-(2-羥苯甲醯基)胺基)辛酸之鹽的固體組成物
CN110294800B (zh) * 2018-03-22 2022-03-04 齐鲁制药有限公司 一种索玛鲁肽的制备方法
WO2019195126A1 (en) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
HRP20221054T1 (hr) * 2018-04-05 2022-11-11 Sun Pharmaceutical Industries Limited Novi analozi glp-1
EP3773475A1 (en) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110386974B (zh) * 2018-04-19 2022-12-09 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
WO2019211451A1 (en) 2018-05-04 2019-11-07 Novo Nordisk A/S Gip derivatives and uses thereof
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020084126A1 (en) * 2018-10-26 2020-04-30 Novo Nordisk A/S Stable semaglutide compositions and uses thereof
CN109180801B (zh) * 2018-11-01 2021-08-13 汉肽生物医药集团有限公司 一种合成索玛鲁肽的方法
WO2020115049A1 (en) 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues
EP3897570A1 (en) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
EP3897582B1 (en) 2018-12-21 2024-09-11 Novo Nordisk A/S Process of spray drying of glp-1 peptide
MA54807A (fr) 2019-01-24 2022-04-27 Novo Nordisk As Compacteur à rouleaux et procédé de granulation à sec utilisant un compacteur à rouleaux
KR20210136014A (ko) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
WO2020169658A2 (en) 2019-02-20 2020-08-27 Novo Nordisk A/S Aminoacyl-trna synthetases and uses hereof
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
WO2020190757A1 (en) 2019-03-15 2020-09-24 Novetide Ltd. Improved processes for the preparation of semaglutide
EP3938094A1 (en) 2019-03-15 2022-01-19 Novo Nordisk A/S Process for spray drying a glp-1 peptide
CN111748019A (zh) * 2019-03-29 2020-10-09 深圳翰宇药业股份有限公司 一种多肽衍生化合物的合成方法
EP3947451A1 (en) 2019-04-01 2022-02-09 Novo Nordisk A/S Antibodies directed against liraglutide and use thereof
CA3136163A1 (en) * 2019-04-11 2020-10-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
KR20220010553A (ko) * 2019-05-21 2022-01-25 메디뮨 리미티드 시클로덱스트린계 주사용 sglt2 억제제와 인크레틴 펩티드의 공동제형
BR112022002189A2 (pt) 2019-09-02 2022-04-26 Novo Nordisk As Processo de produção de um comprimido, e, comprimido
EP4031183A1 (en) * 2019-09-16 2022-07-27 BioMarin Pharmaceutical Inc. Cnp variants and conjugates thereof
CN110590934B (zh) * 2019-09-25 2020-12-08 北京乐普医药科技有限公司 一种glp-1化合物
RS65780B1 (sr) 2019-11-06 2024-08-30 Novo Nordisk As Semaglutid u lečenju alchajmerove demencije
EP3819308A1 (en) 2019-11-07 2021-05-12 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of derivatized amino acids
JP2023502004A (ja) 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
WO2021105393A1 (en) 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CN119529057A (zh) * 2019-12-30 2025-02-28 甘李药业股份有限公司 长效glp-1化合物
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN119841865A (zh) 2020-02-07 2025-04-18 加舒布鲁姆生物公司 杂环glp-1激动剂
BR112022016100A2 (pt) 2020-02-14 2022-10-04 G2Gbio Inc Composição farmacêutica compreendendo microgrânulos de liberação sustentada incluindo análogo de glp-1 ou sal farmaceuticamente aceitável do mesmo
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
US12527844B2 (en) 2020-02-18 2026-01-20 Novo Nordisk A/S Pharmaceutical formulations
WO2021205388A2 (en) 2020-04-10 2021-10-14 Fresenius Kabi Oncology Limited An improved process for the preparation of semaglutide side chain
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
ES3054856T3 (en) 2020-04-29 2026-02-06 Novo Nordisk As Solid compositions comprising a glp-1 agonist and histidine
AR122579A1 (es) * 2020-06-12 2022-09-21 Lilly Co Eli Proceso para preparar un agonista dual glp-1 / glucagón
IL299707A (en) 2020-07-22 2023-03-01 Novo Nordisk As Co-agonists for GLP-1 and GIP receptors
LT4192831T (lt) 2020-08-06 2026-02-10 Gasherbrum Bio, Inc. Heterocikliniai glp#1 agonistai
KR20230073200A (ko) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 항체-tlr 작용제 접합체, 그 방법 및 용도
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
IL302159A (en) 2020-11-06 2023-06-01 Novo Nordisk As GLP-1 drug inhibitors and uses thereof
TW202440619A (zh) 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
BR112023019389A2 (pt) 2021-03-25 2023-11-28 Brightgene Bio Medical Tech Co Ltd Compostos, agonista de receptor duplo de gip e glp-1, composição farmacêutica compreendendo os mesmos, uso dos mesmos e método para prevenir e/ou tratar doenças associadas a distúrbios metabólicos
KR20240004342A (ko) 2021-04-03 2024-01-11 암브룩스, 인코포레이티드 항-her2 항체-약물 접합체 및 이의 용도
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
US20250320252A1 (en) 2021-06-09 2025-10-16 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
JP2024521398A (ja) 2021-06-10 2024-05-31 アンタグ セラピューティクス エーピーエス 肥満及び肥満関連障害の治療
CA3222421A1 (en) 2021-06-23 2022-12-29 Peptron, Inc. Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof
CN117561072A (zh) * 2021-06-25 2024-02-13 甘李药业股份有限公司 含glp-1化合物的药物组合物
EP4360642A4 (en) 2021-06-25 2025-09-10 Gan & Lee Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION OF PCSK9 INHIBITOR AND GLP-1 RECEPTOR AGONIST
WO2023285334A1 (en) 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
CN116635402B (zh) 2021-07-14 2024-03-15 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
CA3223236A1 (en) 2021-07-15 2023-01-19 Thomas Kvistgaard Vilhelmsen Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN116410297A (zh) * 2021-07-19 2023-07-11 内蒙古博睿精创科技有限公司 长效glp-1多肽类似物及其制备方法和应用
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
EP4400105A4 (en) 2021-09-08 2025-11-12 Shionogi & Co MEDICINE INTENDED FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO ANTI-OBESITY ACTIVITY
MX2024005705A (es) 2021-11-10 2024-05-24 I2O Therapeutics Inc Composiciones de liquidos ionicos.
AR127945A1 (es) 2021-12-13 2024-03-13 Novo Nordisk As Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
JP2025509281A (ja) 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
CN118973602A (zh) 2022-03-30 2024-11-15 诺和诺德股份有限公司 配制方法
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
AR129270A1 (es) 2022-05-10 2024-08-07 Novo Nordisk As Profármacos y usos de los mismos
EP4529454A1 (en) 2022-05-23 2025-04-02 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
CN119907661A (zh) 2022-07-05 2025-04-29 G2G生物公司 含有司美格鲁肽或其药学上可接受的盐的缓释微球制剂及其制备方法
EP4593864A1 (en) 2022-09-28 2025-08-06 Zealand Pharma A/S Methods for treating obesity
WO2024079043A1 (en) 2022-10-10 2024-04-18 Bachem Holding Ag Method of manufacturing a peptide with a lysine derivative
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
AU2023397760A1 (en) 2022-12-16 2025-06-26 Peptron, Inc. Sustained-release microspheres including glp-1 receptor agonist or pharmaceutically acceptable salt thereof and use thereof
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法
KR20250141711A (ko) 2022-12-30 2025-09-29 알지파마 에이에스 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
AU2024233842A1 (en) 2023-03-06 2025-09-04 Ascendis Pharma A/S Multi-albumin binding compounds
CN120936383A (zh) 2023-03-06 2025-11-11 阿森迪斯药物股份有限公司 含白蛋白结合部分的药物的化合物
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
KR20250167609A (ko) 2023-03-30 2025-12-01 노보 노르디스크 에이/에스 융합 화합물 및 그 용도
WO2024234320A1 (zh) * 2023-05-17 2024-11-21 南京知和医药科技有限公司 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
CN121263433A (zh) 2023-06-09 2026-01-02 太阳医药工业有限公司 Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
JP2024180368A (ja) 2023-06-15 2024-12-26 ノヴォ ノルディスク アー／エス シクロデキストリンを含む医薬製剤
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025078040A1 (en) 2023-10-09 2025-04-17 Bachem Holding Ag Lysine salt and method of manufacturing a lysine derivative
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
WO2025106773A1 (en) 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
WO2025114501A1 (en) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonists of the glp-1, gip, and amylin receptors
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
US20250326814A1 (en) 2024-02-06 2025-10-23 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684801A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684802A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
GB202403746D0 (en) 2024-03-15 2024-05-01 New Roger Randal Charles Formulations demonstrating an oral depot effect
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2026008836A1 (en) 2024-07-05 2026-01-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2026013135A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding reagents
WO2026013136A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding compounds
WO2026013138A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Compounds with improved albumin-binding

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE193541T1 (de) 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
RU2214419C2 (ru) * 1996-08-30 2003-10-20 Ново Нордиск А/С Glp-1 производные
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
ATE466028T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
AU2712899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU2610599A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
ES2230912T3 (es) 1998-12-07 2005-05-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogo de glp-1.
AU754770B2 (en) 1999-05-17 2002-11-21 Conjuchem Biotechnologies Inc. Long lasting insulinotropic peptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2003519664A (ja) 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１誘導体の経上皮送達
NZ525577A (en) 2000-12-07 2005-05-27 Lilly Co Eli Glucagon-Like Peptide 1 heterologous fusion proteins for the treatment of non-insulin dependent diabetes mellitus
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
ATE382057T1 (de) 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
MXPA04006679A (es) 2002-01-08 2004-11-10 Lilly Co Eli Analogos extendidos de peptido-1 de tipo glucagon.
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EA200401345A1 (ru) 2002-04-10 2005-08-25 Эли Лилли Энд Компани Лечение гастропареза
CN1750842A (zh) 2003-02-19 2006-03-22 研究及应用科学协会股份有限公司 Glp－1的类似物
HRP20050683A2 (en) 2003-03-19 2006-07-31 Eli Lilly And Company Polyethylene glycol linked glp-1 compounds
WO2004099246A2 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
JP2007501812A (ja) * 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用
MXPA06002941A (es) 2003-09-19 2006-05-31 Novo Nordisk As Derivados de enlace a albumina de peptidos terapeuticos.
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
CN101005857A (zh) 2004-07-08 2007-07-25 诺和诺德公司 多肽延长标记
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
CN102772787A (zh) 2004-11-12 2012-11-14 诺和诺德公司 促胰岛素肽的稳定制剂
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CA2596926A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds

Also Published As

Publication number Publication date
RU2434019C2 (ru) 2011-11-20
JP4585037B2 (ja) 2010-11-24
PT2322546E (pt) 2016-01-22
HUE028194T2 (en) 2016-12-28
EP1863839B1 (en) 2010-08-04
AU2006224536B9 (en) 2012-05-10
BR122019002626A2 (index.php) 2019-04-02
HUS1800019I1 (hu) 2018-06-28
BE2018C016I2 (index.php) 2025-09-05
DE602006015928D1 (de) 2010-09-16
CN104017062A (zh) 2014-09-03
US8536122B2 (en) 2013-09-17
ATE476446T1 (de) 2010-08-15
IL184051A (en) 2015-08-31
CN101133082B (zh) 2016-01-13
NO2018023I1 (index.php) 2018-07-05
CA2601784C (en) 2013-12-24
PL1863839T3 (pl) 2011-01-31
JP2010116407A (ja) 2010-05-27
RU2007134156A (ru) 2009-04-27
CN101133082A (zh) 2008-02-27
AU2006224536B2 (en) 2012-04-05
EP2322546A1 (en) 2011-05-18
MX2007011220A (es) 2007-10-17
DK2322546T3 (en) 2015-12-14
US20120295847A1 (en) 2012-11-22
JP2008533105A (ja) 2008-08-21
US20090156478A1 (en) 2009-06-18
TWI372629B (en) 2012-09-21
NO20075342L (no) 2007-12-18
PT1863839E (pt) 2010-11-10
EP2322546B1 (en) 2015-09-30
EP1863839A2 (en) 2007-12-12
AU2006224536A1 (en) 2006-09-21
KR20070120089A (ko) 2007-12-21
IL184051A0 (en) 2007-10-31
KR101205272B1 (ko) 2013-01-11
CA2601784A1 (en) 2006-09-21
TW200942255A (en) 2009-10-16
US8129343B2 (en) 2012-03-06
BRPI0607762B1 (pt) 2019-05-07
TW200700433A (en) 2007-01-01
WO2006097537A2 (en) 2006-09-21
WO2006097537A3 (en) 2007-01-25
NO337946B1 (no) 2016-07-18
ZA200707261B (en) 2008-05-28
ES2557313T3 (es) 2016-01-25
ES2350051T3 (es) 2011-01-17
DK1863839T3 (da) 2010-11-22
PL2322546T3 (pl) 2016-03-31
BRPI0607762B8 (pt) 2021-05-25
TWI362392B (en) 2012-04-21
NL300936I2 (nl) 2018-08-07
JP2013063984A (ja) 2013-04-11
CN104402989A (zh) 2015-03-11
RU2434019C3 (ru) 2020-07-20
BRPI0607762A2 (pt) 2010-03-23

Similar Documents

Publication Publication Date Title
JP5209463B2 (ja) アシル化ｇｌｐ−１化合物
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
JP5606314B2 (ja) Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途
US9012398B2 (en) Acylated exendin-4 compounds
JP5476304B2 (ja) グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
WO2009030774A1 (en) Truncated glp-1 derivatives and their therapeutical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110623

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111005

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130221

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160301

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5209463

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153